- ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
-
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
- -
-
-
- Aryl ureas as kinase inhibitors
-
This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VE
- -
-
-
- DIARYL UREAS AND COMBINATIONS
-
The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I) : B-NH-C(O)-NH-L-M-L1-(Q)1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. Each Q is independently C(O)R4, C(O)OR4 and C(O)NR4R5; and L' is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.
- -
-
Page/Page column 45
(2008/06/13)
-
- TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS
-
The present invention provides compositions and methods for treating cancer with sorafenib, wherein the cancer that has acquired resistance to another therapeutic agent, such as kinase inhibitors. Sorafinb can also be used to treat cancers which have become refractory to other chemotherapeutic agents .
- -
-
Page/Page column 15
(2010/11/27)
-
- TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS
-
The present invention provides compositions and methods for treating cancers ; which have acquired resistance to a KIT inhibitor by administering effective amounts of sorafenib.
- -
-
Page/Page column 11-12
(2012/04/23)
-
- DIARYL UREAS WITH KINASE INHIBITING ACTIVITY
-
The present invention provides methods of using aryl ureas to treat diseases and conditions associated with signal transduction pathways comprising at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. The present invention also provides compositions and methods for identifying conditions and diseases which can be modulated with compounds of the present invention. These methods facilitate the selection of subjects who can be efficiently treated with compounds of the present invention. Additionally, the invention provides methods for monitoring subjects who have been administered a compound of the present invention.
- -
-
-
- Aryl ureas with angiogenisis inhibiting activity
-
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
- -
-
-
- Aryl ureas as kinase inhibitors
-
This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
- -
-
-
- Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
-
This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
- -
-
-
- Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
-
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
-
- omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
-
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
-
- OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
-
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
Page/Page column 23
(2010/01/31)
-
- Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
-
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
- -
-
-
- Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
-
This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
-
- Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
-
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
-